1. Home
  2. ANVS

as of 02-06-2026 3:46pm EST

$2.54
+$0.10
+4.10%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Founded: 2008 Country:
United States
United States
Employees: N/A City: MALVERN
Market Cap: 111.3M IPO Year: 2020
Target Price: $13.50 AVG Volume (30 days): 507.8K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.44 EPS Growth: N/A
52 Week Low/High: $1.11 - $5.50 Next Earning Date: 03-20-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered ANVS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 72.90%
72.90%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Annovis Bio Inc. (ANVS)

Buy
ANVS Nov 24, 2025

Avg Cost/Share

$4.07

Shares

39,200

Total Value

$159,886.07

Owned After

2,482,028

SEC Form 4

Buy
ANVS Nov 14, 2025

Avg Cost/Share

$2.11

Shares

15,000

Total Value

$31,650.00

Owned After

2,482,028

SEC Form 4

Share on Social Networks: